Envestnet Asset Management Inc. Raises Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Envestnet Asset Management Inc. increased its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 68.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,004 shares of the biotechnology company's stock after purchasing an additional 24,293 shares during the quarter. Envestnet Asset Management Inc.'s holdings in ADMA Biologics were worth $1,029,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Barclays PLC lifted its position in ADMA Biologics by 192.2% in the 3rd quarter. Barclays PLC now owns 528,629 shares of the biotechnology company's stock valued at $10,567,000 after acquiring an additional 347,692 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of ADMA Biologics by 19.4% during the 3rd quarter. Franklin Resources Inc. now owns 167,644 shares of the biotechnology company's stock worth $3,351,000 after acquiring an additional 27,180 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $368,000. Lord Abbett & CO. LLC purchased a new position in shares of ADMA Biologics during the third quarter valued at approximately $61,858,000. Finally, Principal Financial Group Inc. increased its stake in ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after buying an additional 1,059,394 shares during the period. Institutional investors own 75.68% of the company's stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of ADMA stock traded up $0.19 during trading hours on Monday, reaching $23.71. The company had a trading volume of 2,313,467 shares, compared to its average volume of 3,686,873. The stock has a fifty day moving average of $19.60 and a 200-day moving average of $18.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a market capitalization of $5.63 billion, a price-to-earnings ratio of 84.68 and a beta of 0.57. ADMA Biologics, Inc. has a 12-month low of $6.72 and a 12-month high of $25.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.